Lopinavir / ritonavir

Phenobarbital

Not recommended association.

No pharmaceutical opinion available for this interaction.

Mechanism

Phenobarbital can induce the metabolism (CYP 3A4) and decrease the plasma concentration of Lopinavir / ritonavir.

Lopinavir / ritonavir can induce the metabolism (CYP 2C9 and CYP 2C19) and decrease the plasma concentration of Phenobarbital.

Lopinavir / ritonavir

Pharmacodynamic effects

Possible decrease of clinical efficacy.

Recommendations

Monitor for signs and symptoms of therapeutic failure.

An increase in dosage may be necessary.

Lopinavir/ritonavir must not be administered once daily in combination with this drug.

Alternative solution(s)

Phenobarbital

Pharmacodynamic effects

Possible decrease of clinical efficacy.

Recommendations

Avoid if possible. Use an alternative or monitor patient closely.

Monitor for signs and symptoms of therapeutic failure.

Titrate dose based on patient response and tolerability.

Alternative solution(s)

Gabapentin, pregabalin, leviracetam.

Monitor

Tests

Phenobarbital

Lopinavir plasma level

CD4+

Viral load HIV

Pharmacokinetic parameters

Comment

Reference
  • 2377
    Lopinavir/ritonavir (Kaletra). Coorporation Abbvie, Quebec, Canada, 5 oct 2017.
  • 122
    Ritonavir (Norvir), Corporation AbbVie, Quebec, Canada, 25 septembre 2018.